Literature DB >> 20872278

Myocardial remodeling, an overview.

Dennis V Cokkinos1, Costas Pantos.   

Abstract

Mesh:

Year:  2011        PMID: 20872278     DOI: 10.1007/s10741-010-9192-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


× No keyword cloud information.
  28 in total

Review 1.  Genomic analysis of left ventricular remodeling.

Authors:  Rizwan Sarwar; Stuart A Cook
Journal:  Circulation       Date:  2009-08-04       Impact factor: 29.690

Review 2.  Cardiac plasticity.

Authors:  Joseph A Hill; Eric N Olson
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

3.  Myostatin activation in patients with advanced heart failure and after mechanical unloading.

Authors:  Isaac George; Lawrence T Bish; Gayathri Kamalakkannan; Christopher M Petrilli; Mehmet C Oz; Yoshifumi Naka; H Lee Sweeney; Simon Maybaum
Journal:  Eur J Heart Fail       Date:  2010-03-27       Impact factor: 15.534

4.  Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications.

Authors:  Leonardo Bolognese; Aleksandar N Neskovic; Guido Parodi; Giampaolo Cerisano; Piergiovanni Buonamici; Giovanni M Santoro; David Antoniucci
Journal:  Circulation       Date:  2002-10-29       Impact factor: 29.690

5.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.

Authors:  Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2010-01-19       Impact factor: 24.094

Review 6.  Myocardial hibernation: a delicate balance.

Authors:  Gerd Heusch; Rainer Schulz; Shahbudin H Rahimtoola
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-24       Impact factor: 4.733

Review 7.  Controversies in ventricular remodelling.

Authors:  Lionel H Opie; Patrick J Commerford; Bernard J Gersh; Marc A Pfeffer
Journal:  Lancet       Date:  2006-01-28       Impact factor: 79.321

8.  Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.

Authors:  B Daan Westenbrink; Willem-Peter T Ruifrok; Adriaan A Voors; Ronald G Tilton; Dirk J van Veldhuisen; Regien G Schoemaker; Wiek H van Gilst; Rudolf A de Boer
Journal:  Cardiovasc Res       Date:  2010-02-05       Impact factor: 10.787

9.  MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.

Authors:  Scot J Matkovich; Wei Wang; Yizheng Tu; William H Eschenbacher; Lisa E Dorn; Gianluigi Condorelli; Abhinav Diwan; Jeanne M Nerbonne; Gerald W Dorn
Journal:  Circ Res       Date:  2009-11-05       Impact factor: 17.367

Review 10.  Return to the fetal gene program protects the stressed heart: a strong hypothesis.

Authors:  Mitra Rajabi; Christos Kassiotis; Peter Razeghi; Heinrich Taegtmeyer
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more
  11 in total

1.  Prediction of left ventricular remodelling by radionuclide imaging.

Authors:  Constantinos D Anagnostopoulos; Dennis V Cokkinos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

2.  CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages.

Authors:  Lei Yang; Li Ni; Quanlu Duan; Xingxu Wang; Chen Chen; Song Chen; Sandip Chaugai; D C Zeldin; Jia Rong Tang; Dao Wen Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-02-14       Impact factor: 3.072

3.  Myocardial perfusion MRI shows impaired perfusion of the mouse hypertrophic left ventricle.

Authors:  Bastiaan J van Nierop; Bram F Coolen; Noortje A Bax; Wouter J R Dijk; Elza D van Deel; Dirk J Duncker; Klaas Nicolay; Gustav J Strijkers
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-28       Impact factor: 2.357

4.  S-nitrosylation of c-Jun N-terminal kinase mediates pressure overload-induced cardiac dysfunction and fibrosis.

Authors:  Miao Zhou; Ji-Yu Chen; Meng-Lin Chao; Chao Zhang; Zhi-Guang Shi; Xue-Chun Zhou; Li-Ping Xie; Shi-Xiu Sun; Zheng-Rong Huang; Shan-Shan Luo; Yong Ji
Journal:  Acta Pharmacol Sin       Date:  2021-05-19       Impact factor: 6.150

5.  Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism.

Authors:  Karla Reichert; Helison Rafael Pereira do Carmo; Anali Galluce Torina; Daniela Diógenes de Carvalho; Andrei Carvalho Sposito; Karlos Alexandre de Souza Vilarinho; Lindemberg da Mota Silveira-Filho; Pedro Paulo Martins de Oliveira; Orlando Petrucci
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

6.  Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.

Authors:  Kenneth M Borow; Alex Yaroshinsky; Barry Greenberg; Emerson C Perin
Journal:  Circ Res       Date:  2019-07-18       Impact factor: 17.367

7.  LncRNA NRON alleviates atrial fibrosis through suppression of M1 macrophages activated by atrial myocytes.

Authors:  Fei Sun; Zhixiang Guo; Chengxin Zhang; Hong Che; Wenhui Gong; Zhiming Shen; Yinglu Shi; Shenglin Ge
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

Review 8.  Cellular and Molecular Mechanism of Traditional Chinese Medicine on Ventricular Remodeling.

Authors:  Yong-Chun Zhu; Bo Liang; Ning Gu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

9.  Phenotyping of left and right ventricular function in mouse models of compensated hypertrophy and heart failure with cardiac MRI.

Authors:  Bastiaan J van Nierop; Hans C van Assen; Elza D van Deel; Leonie B P Niesen; Dirk J Duncker; Gustav J Strijkers; Klaas Nicolay
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

10.  MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo.

Authors:  Yao Xu; Chen Liang; Ying Luo; Tongcun Zhang
Journal:  J Cell Mol Med       Date:  2020-12-08       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.